Status:
COMPLETED
Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects
Lead Sponsor:
GlaxoSmithKline
Collaborating Sponsors:
Adelphi Values
Conditions:
Hypertension, Pulmonary
Eligibility:
All Genders
18+ years
Brief Summary
GlaxoSmithKline (GSK) is embarking on a clinical program to assess the treatment of PAH with an Angiotensin converting enzyme 2 (ACE2). This new treatment may require subcutaneous administration, in c...
Eligibility Criteria
Inclusion
- Male or female, at least 18 years of age.
- Subject is willing and able to provide written informed consent.
- Subject must have a diagnosis of symptomatic Pulmonary Arterial Hypertension Type I as per the World Health Organization (WHO) clinical classification system.
- Subject must have the cognitive and linguistic capabilities sufficient to allow them to actively participate in an interview lasting 30 minutes.
Exclusion
- Subject has a diagnosis of other cardiac or pulmonary disease.
- Subject has a Type II-V diagnosis of PAH, as per the WHO clinical classification system.
- Subject is currently receiving treatment for PAH via modes of administration other than intravenously or orally.
Key Trial Info
Start Date :
November 22 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 10 2018
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03304548
Start Date
November 22 2017
End Date
April 10 2018
Last Update
April 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Boston, Massachusetts, United States, 02210